Montreal, Quebec--(Newsfile Corp. - January 28, 2026) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the...
NCI-Led Study Shows Median PFS of 9.6 Months Results Presented at AACR Special Conference on Innovations in Prostate Cancer PRINCETON, N.J.,...
Company ready to commence regulatory process to secure access to U.S. market for Australian Chestnut Extract as a botanical product...
Paper defines the mechanism by which COUR Nanoparticles induce antigen-specific immune toleranceCHICAGO, Jan. 28, 2026 (GLOBE NEWSWIRE) -- COUR Pharma,...
IND clearance marks the first ever cellular rejuvenation therapy using partial epigenetic reprogramming to reach human clinical trialsBOSTON, Jan. 28,...
-- Collaboration will advance a next generation gene editing approach by combining Seamless’ expertise in developing highly precise and efficient...
AUSTIN, Texas, Jan. 27, 2026 /PRNewswire/ -- IgniteTech, the AI-DNA Enterprise Software company, today announced it has been named as...
NASHUA, N.H., Jan. 27, 2026 /PRNewswire/ -- Resonetics announced today that it has signed an agreement to acquire Resolution Medical, a...
Precise MRD™ to transition from research-use-only into a limited clinical launch in March 2026SALT LAKE CITY, Jan. 27, 2026 (GLOBE...
Company expands its ADC pipeline and patent estate for novel, differentiated ADCs New pipeline candidate AKTX-102 leverages Akari’s proprietary PH1...
WESTLAKE VILLAGE, Calif., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing...
- Cogent will submit the PEAK New Drug Application (NDA) under previously announced RTOR designation; on track to complete NDA...
A major technological advance in DNA writing enables researchers to construct and create in the language of biology The Genyro...
A major technological advance in DNA writing enables researchers to construct and create in the language of biologyPASADENA, Calif., Jan....
Four abstracts highlighting clinical data and real-world experience with MIPLYFFA accepted for presentation, including an oral presentation by Caroline Hastings,...
Tokyo, Japan and Cambridge, UK, 26 January 2026 - Nxera Pharma Co. Ltd (“Nxera”; TSE 4565) will announce its earnings results...
A consumer-focused examination of NAD+ injections, NAD+ supplements, NAD+ peptides, NAD+ dosage protocols, documented NAD+ benefits, and potential NAD+ side...
HOUSTON, TX, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in...
Independent evaluation explores patent-pending pressurized air throat hit technology, no-heat no-vapor valve mechanism, third-party material safety testing, and oral fixation...
HAMILTON, BERMUDA / ACCESS Newswire / January 23, 2026 / Altamira Therapeutics Ltd. ("Altamira" or the "Company") (OTCID:CYTOF), a company...